Jean Cheikh

Jun 20, 2024 | nature.com | Jean Cheikh

AbstractPhiladelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) constitutes a distinctive cytogenetic entity associated with challenging outcomes, particularly in adult patients. Current upfront chemotherapy-tyrosine kinase inhibitor (TKI)-based therapies include first, second and third-generation TKIs that have revolutionized patient outcomes including molecular remission and overall survival.

Dec 6, 2023 | frontiersin.org | Patient-Centered Research |Jean Cheikh |Catarina Geraldes |Jack Khouri

1 IntroductionThe incidence of multiple myeloma (MM) is highly variable across countries but has increased uniformly since 1990 (1, 2). This hematologic cancer disproportionately affects older patients (median age of diagnosis >70 years) in whom the burden of adverse events and decline in health-related quality of life (HRQoL) can be particularly high (3, 4).